Effect of the consumption of a probiotic strain on the prevention of post-operative recurrence in Crohn's disease
NCT ID NCT01698970
First seen Oct 21, 2026 · Last updated Oct 22, 2026 · Updated 1 time
Summary
A double-blind, multicentre, stratified by centre, randomised, parallel study with two groups of adult patients operated on for Crohn's disease, to determine if oral ingestion of probiotics could prevent the appearance of Crohn's disease recurrent endoscopic ileo-colonic lesions 12 months after surgery. Patients will consume 900 mg/day of active product (N=56) or control product (N=56) during one year.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
122 people
The number who actually took part.
- Start date
-
Feb 2004
- Finished
-
Mar 2010
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male/female at least 18 years old * Diagnosis of Crohn's disease defined by the criteria usually adopted (Gower-Rousseau, 1994) * Crohn's disease mainly limited to the terminal ileum and/or the ascending and transverse colon * Diagnosis of Crohn's disease in agreement with surgical specimen analysis * Patient having given its written consent to take part in the study * Complete resection of all main macroscopic ileo-colonic lesions, as shown by inspection at surgery * To have an ileo-colic resection (right, transverse, left) with an anastomosis that can be inspected by endoscopy * Ability to start oral nutrition and therefore the consumption of the study product within 21 days of surgery * Patient receiving no antibiotics at the beginning of the product consumption Exclusion Criteria: * One or more intestinal resection during the 5 last years before the last surgery * Presence of any severe additional disease * For female patient : pregnancy or breast feeding * For pre-menopausal female patient : no effective contraceptive methods used (combined oestrogen-progestogen pill or Intrauterine Device) * Patient currently in an exclusion period following participation in another clinical trial * Patient in a situation which in the investigator's opinion could interfere with optimal participation in the present study or could constitute a special risk for the patient * Significant presence of Crohn's disease in other intestinal tracts * Small bowel cumulative resection exceeding 1 meter * Patient with ileostomy * Subtotal colectomy with ileo-rectal anastomosis * Severe post-operative septic complications (fistula, peritonitis), leading to administration of more than 15 days of post-operative antibiotherapy) * Intake of unauthorised treatments (mesalazine, olsalazine or sulfasalazine, 5-Aminosalicylates (5-ASA) or 4-Aminosalicylates (4-ASA)) ; corticoïds and immunosuppressors) after surgery except corticoids which will have to be stopped within 6 weeks after surgery according to standardised stepwise dose reductions * Patient under artificial nutrition * Subject with a loss of personal liberty, by administrative or judicial decision, or major with a legal guardian
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Crohn's disease are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Huriez - Service des maladies de l'appareil digestif et de la nutrition
Lille, 59037, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can donated umbilical cord cells calm inflamed guts?
- Gut bacteria probiotic put to the test against bowel inflammation
- Can a personalized diet heal the gut in Crohn's disease?
- Gut chemical serotonin under scrutiny in IBD research
- Gut microbes eyed as hidden trigger of IBD belly pain
- Biopsy of a biopsy: scientists map the genes behind gut ulcer healing